National Centre for Pharmacoeconomics

National Centre for
Pharmacoeconomics

NCPE Ireland

Olaparib (Lynparza®) in combination with bevacizumab (1L maintenance HRD positive ovarian cancer). HTA ID: 21011

Olaparib in combination with bevacizumab is indicated for the maintenance treatment of adult patients with advanced (FIGO stages III and IV) high-grade epithelial ovarian, fallopian tube or primary peritoneal cancer who are in response (complete or partial) following completion of first-line platinum-based chemotherapy in combination with bevacizumab and whose cancer is associated with homologous recombination deficiency (HRD) positive status defined by either a BRCA1/2 mutation and/or genomic instability.

 

 

NCPE Assessment Process Complete
Rapid review commissioned 24/03/2021
Rapid review completed 28/04/2021
Rapid Review outcome A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of olaparib in combination with bevacizumab compared with the current standard of care.
Full pharmacoeconomic assessment commissioned by HSE 31/05/2021
Pre-submission consultation with Applicant Scheduled
Current Status Pre-submission consultation scheduled